North China Pharmaceutical Co., Ltd. (600812.SH) Latest Company News

Oct 23, 2026, 09:37 UTC
China's National Medical Products Administration approved North China Pharmaceutical's registration of piperacillin sodium and tazobactam sodium for injection with sodium chloride, making the company the first domestic firm approved for the product.
Source:
- finance.sina.cn
Sep 21, 2026, 09:58 UTC
China's A-share major indices closed higher on September 21, 2026, with the Shanghai Composite up 0.97% at 3949.91, the Shenzhen Component up 0.65% at 13730.02, and the ChiNext up 0.80% at 3399.59, as over 4,500 stocks advanced and innovative drug concept stocks surged.
Source:
- news.cnfol.com
- m.21jingji.com
Aug 27, 2026, 08:42 UTC
North China Pharmaceutical's subsidiary Shenzhen Huayao South Pharmaceutical received approval from China's National Medical Products Administration on August 24, 2026, to add a 1.8g specification of lysine acetylsalicylate for injection, with both 0.9g and 1.8g specifications passing generic drug consistency evaluation.
Source:
- finance.sina.cn
Aug 21, 2026, 11:36 UTC
North China Pharmaceutical announced its first-half 2026 results: revenue of 4.220 billion yuan, down 20.01% year-on-year; net profit attributable to shareholders of 63.8459 million yuan, down 48.30% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 11:36 UTC
North China Pharmaceutical's subsidiary Jintan received approval from China's National Medical Products Administration to conduct clinical trials for a hexavalent recombinant norovirus vaccine.
Source:
- finance.sina.cn
Aug 3, 2026, 08:25 UTC
North China Pharmaceutical and its subsidiaries Huamin Company and Nanfang Company had 8 drugs preliminarily selected in the 12th national centralized drug procurement, with the publicity period from July 31 to August 5, 2026, and the procurement cycle ending December 31, 2029.
Source:
- finance.sina.cn

600812.SH

China's National Medical Products Administration approved North China Pharmaceutical's registration of piperacillin sodium and tazobactam sodium for injection with sodium chloride, making the company the first domestic firm approved for the product.

China's A-share major indices closed higher on September 21, 2026, with the Shanghai Composite up 0.97% at 3949.91, the Shenzhen Component up 0.65% at 13730.02, and the ChiNext up 0.80% at 3399.59, as over 4,500 stocks advanced and innovative drug concept stocks surged.

North China Pharmaceutical announced its first-half 2026 results: revenue of 4.220 billion yuan, down 20.01% year-on-year; net profit attributable to shareholders of 63.8459 million yuan, down 48.30% year-on-year.

North China Pharmaceutical's subsidiary Jintan received approval from China's National Medical Products Administration to conduct clinical trials for a hexavalent recombinant norovirus vaccine.

North China Pharmaceutical and its subsidiaries Huamin Company and Nanfang Company had 8 drugs preliminarily selected in the 12th national centralized drug procurement, with the publicity period from July 31 to August 5, 2026, and the procurement cycle ending December 31, 2029.